Psilocybin Continues Down The Road Towards Legalization With Second Designation From FDA


If you thought the legalization of Marijuana was groundbreaking (and it definitely was) the wait may soon be up for Magic Mushrooms to join the ranks. Today, only a year after Psilocybin was designated as a breakthrough therapy drug for depression, today the FDA has designated it for a second time to further new research into the psychedelic drug.

In simple terms, this second designation means that the FDA has seen so much potential from psilocybin studies over the last year, that they’re now giving non-profit medical research organization Usona the power to investigate further with the substance. In a recent article published by Medscape, Charles Raison, Usona’s director of clinical and translational research, touched on the data behind reseach into the use of psilocybin to treat Major Depressive Disorder (MDD). Raison said that concerning MDD, “the available data suggest that psilocybin may offer a substantial clinical improvement over existing therapies”.

As Denver became the first city to have decriminalized hallucinogenic mushrooms, we’re feeling optimistic about the current state of psychedelic research. Although we may have to wait for a few years for updated info on the state of psilocybin research as phase two is expected to reach it’s completion by early 2021, we’re excited about this new development in the wild world of psychedelics. See the full Medscape article here and enjoy!